Malawi vs Nigeria: Statin use vs. average non-HDL cholesterol levels
Malawi
2.5
in 2018
Nigeria
2.6
in 2018
Malawi rank
190th
Nigeria rank
187th
Statin use vs. average non-HDL cholesterol levels over time
- Malawi
- Nigeria
How they compare
Nigeria currently reports 2.6 against 2.5 in Malawi, a difference of 0.1.
Across all 39 years both countries report, Nigeria has been ahead every year.
Malawi ranks 190th and Nigeria ranks 187th of 191 countries.
Nigeria has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Malawi | Nigeria | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 2.04 | 2.14 | 0.1 | Nigeria |
| 1990s | 2.11 | 2.26 | 0.15 | Nigeria |
| 2000s | 2.22 | 2.43 | 0.21 | Nigeria |
| 2010s | 2.42 | 2.57 | 0.1444 | Nigeria |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Malawi or Nigeria?
- Nigeria, at 2.6 against 2.5 in Malawi as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Malawi and Nigeria?
- 0.1, with Nigeria ahead.
- How many years of comparable data are there for Malawi and Nigeria?
- 39 years are reported by both, from 1980 to 2018.
- How do Malawi and Nigeria rank globally for statin use vs. average non-hdl cholesterol levels?
- Malawi ranks 190th and Nigeria ranks 187th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.